HOWL — Werewolf Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Macy's, Conduent, Pfizer
U.S. STOCKS ON THE MOVE-Netflix, Rite Aid, TotalEnergies SE
U.S. STOCKS ON THE MOVE-CDK Global, Sprinklr, Biophytis
Werewolf Therapeutics gains as Jazz buys rights to cancer drug candidate
Brief: Jazz Pharmaceuticals And Werewolf Therapeutics Announce Exclusive Global License And Collaboration Agreement To Develop Wtx-613, A Differentiated, Conditionally-Activated IFNα Indukine Molecule
Brief: Werewolf Therapeutics Reports Fourth Quarter 2021 And Full Year 2021 Financial Results
Brief: Werewolf Added To Nasdaq Biotechnology Index
Brief: Werewolf Therapeutics To Present Preclinical Data On Indukine Molecules At 63rd American Society Of Hematology Annual Meeting
Brief: Werewolf Therapeutics Reports Third Quarter 2021 Financial Results And Business Update
Werewolf Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Werewolf Therapeutics Reports Quarterly Loss Per Share Of $3.82
Brief: Werewolf Therapeutics Reports Second Quarter 2021 Financial Results And Business Update
Brief: Werewolf Therapeutics Announces Its Addition To The Russell 2000® Index
Brief: Werewolf Therapeutics Says Net Loss Was $7.4 Million For Q1 2021, Compared To $3.8 Million For Same Period In 2020
Brief: Werewolf Therapeutics Appoints Mike Sherman To Its Board Of Directors
U.S. STOCKS ON THE MOVE-Vimeo, Moderna, Pieris Pharmaceuticals, Novan, Virgin Galactic
U.S. STOCKS ON THE MOVE-Novan, Lordstown Motors, Shake Shack, United Airlines
Brokerages bet on Werewolf Therapeutics' PREDATOR cancer platform
U.S. RESEARCH ROUNDUP-Cimarex Energy, Dollar General, Werewolf Therapeutics